AbVir Biotherapeutics develops antibody‑based therapeutics aimed at treating viral infections. Their platform leverages engineered antibodies to neutralize pathogens and modulate immune responses, targeting diseases where current treatments are limited. The company focuses on advancing preclinical candidates through rigorous validation to address unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Infectious diseases and immune‑related conditions often lack effective therapeutic options that can precisely target pathogens or dysregulated immune pathways, leading to suboptimal treatment outcomes and safety concerns.
Solution
AbVir Biotherapeutics applies proprietary antibody engineering platforms to create novel therapeutic proteins aimed at these unmet medical needs. By designing and optimizing antibodies and related biologics, the company seeks to improve target specificity, potency, and safety profiles in preclinical models. Their pipeline includes candidates directed against viral pathogens as well as molecules that modulate inflammatory signaling pathways. The approach is intended to generate candidates that can progress to clinical evaluation for both infectious and immune‑mediated diseases.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking advanced biologic candidates for infectious disease treatment and immune‑mediated disorders, as well as research institutions pursuing collaborative development.
Features
- Custom antibody engineering platform enabling rapid design and affinity maturation of therapeutic proteins
- Integrated safety optimization workflow to reduce off‑target effects and immunogenicity
- Preclinical validation pipeline that assesses efficacy in relevant viral infection and inflammation models
- Modular protein formats allowing adaptation to diverse targets across infectious and immune‑related indications
- Proprietary computational tools for epitope selection and antibody‑antigen interaction modeling